Novo Nordisk unveiled its latest data for a weight-loss drug candidate, but shares of the maker of Wegovy and Ozempic tumbled ...

The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...

Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

Novo Nordisk ended its agreement with Hims & Hers for the sale of Wegovy after disagreements over marketing tactics and ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

Novo Nordisk said on Monday it would halt its collaboration with Hims & Hers Health over the sale of weight loss drugs. The ...

Novo Nordisk said in a statement on Monday that direct access to Wegovy would no longer be available to Hims & Hers Health ...

Novo Nordisk reported mostly mild side effects from its experimental weight-loss drug CagriSema, though results upset ...